SSRI for anxiety and depression. Psychiatrist-supervised, not a GP afterthought. Because mental health deserves the same medical rigor as physical health. Discreet monthly delivery.
Sertraline is an SSRI (selective serotonin reuptake inhibitor) used for depression, anxiety, OCD, and PTSD. It works by blocking serotonin reuptake in synapses, increasing serotonin availability. Doses vary by condition (50–200 mg/day). Typical onset is 4–6 weeks; full benefit at 8–12 weeks. Requires monitoring for activation, side effects, and periodically reassessing need for continued treatment.
| Condition | Start Dose | Target | Max | Onset Timeline |
|---|---|---|---|---|
| Depression | 50 mg | 100 mg/day | 200 mg/day | 4–6 weeks (mood); 8–12 weeks (full) |
| Anxiety | 50 mg | 100 mg/day | 200 mg/day | 4–8 weeks; may feel activated first 2 weeks |
| OCD | 50 mg | 150 mg/day | 200 mg/day | 8–12 weeks (compulsions slow to improve) |
| PTSD | 50 mg | 150 mg/day | 200 mg/day | 6–8 weeks (hyperarousal); 12+ weeks (intrusion) |
| Typical Dosing | Increase by 50 mg every 1–2 weeks until symptom relief or max dose; adjust based on response/tolerability | |||
Sertraline selectively inhibits serotonin reuptake, increasing available serotonin in the synaptic cleft. Over weeks, this triggers neuroplastic changes that rebuild emotional regulation circuits.
Sertraline undergoes extensive hepatic metabolism via multiple CYP pathways, which explains its resistance to single-enzyme polymorphisms. Understanding these parameters helps optimize dosing and explains drug interaction potential.
| Bioavailability | ~44% (oral, high first-pass metabolism) |
| Tmax (time to peak) | 4.5–8.4 hours |
| Elimination half-life | 26 hours (parent compound) |
| Active metabolite half-life | N-desmethylsertraline: 62–104 hours (potency: 1/8 of parent) |
| Steady state | 7–10 days (parent), 14–21 days (metabolite) |
| Protein binding | ~98% (primarily albumin and α1-acid glycoprotein) |
| Volume of distribution | ~21 L/kg (highly lipophilic) |
| Primary metabolism | Hepatic — CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 (multiple pathways reduce polymorphism impact) |
| Excretion | Fecal: 40–45%, Renal: 40–45%, Minimal unchanged drug in urine |
| Food effect | Increases peak levels slightly but does not significantly reduce absorption (AUC). Can be taken with or without food. |
Your prescribing psychiatrist will determine your final dosing schedule. These are evidence-based guidelines commonly used in clinical practice.
Sertraline is one of the most-studied SSRIs globally. Below are landmark clinical trials and meta-analyses supporting its efficacy and safety profile.
Sertraline's safety profile is well-established from decades of clinical use. Incidence rates below reflect data from controlled clinical trials at 50–200mg doses.
Sertraline is metabolized via multiple CYP pathways and is a weak inhibitor of CYP2D6. Although its extensive metabolism provides some protection against single-enzyme polymorphisms, several important interactions exist. Your prescribing psychiatrist will review your full medication list.
Connect with a psychiatrist to discuss whether sertraline is right for you.